A phase II study ofDAS181, a novel host directed antiviral for the treatment of influenzainfection
Moss RB, Hansen C, Sanders RL, et al. A phase II study ofDAS181, a novel host directed antiviral for the treatment of influenzainfection. J Infect Dis 2012; 206:1844-51.
A recombinant sialidasefusion protein effectively inhibits human parainfluenza viral infectionin vitro and in vivo
Moscona A, Porotto M, Palmer S, et al. A recombinant sialidasefusion protein effectively inhibits human parainfluenza viral infectionin vitro and in vivo. J Infect Dis 2010; 202:234-41.
Inhibition of primary clinicalisolates of human parainfluenza virus by DAS181 in cell cultureand in a cotton rat model
Jones BG, Hayden RT, Hurwitz JL. Inhibition of primary clinicalisolates of human parainfluenza virus by DAS181 in cell cultureand in a cotton rat model. Antiviral Res 2013; 100:562-6.
Treatment of parainfluenza3 infection with DAS181 in a patient after allogeneic stem celltransplantation
Chen YB, Driscoll JP, McAfee SL, et al. Treatment of parainfluenza3 infection with DAS181 in a patient after allogeneic stem celltransplantation. Clin Infect Dis 2011; 53:e77-80.
Comparison of real-timePCR assays with fluorescent-antibody assays for diagnosis of respiratoryvirus infections in children
Kuypers J,Wright N, Ferrenberg J, et al. Comparison of real-timePCR assays with fluorescent-antibody assays for diagnosis of respiratoryvirus infections in children. J Clin Microbiol 2006; 44:2382-8.
Parainfluenza virus infectionof young children: estimates of the population-based burdenof hospitalization
Weinberg GA, Hall CB, Iwane MK, et al. Parainfluenza virus infectionof young children: estimates of the population-based burdenof hospitalization. J Pediatr 2009; 154:694-9.